GARDEN CITY, N.Y. — February 20, 2026 — Leads & Copy — Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company, has commented on the publication of an independent review article focusing on high-dose inhaled nitric oxide (iNO) delivered at concentrations exceeding the FDA-approved 20 ppm.
The review, titled “The therapeutic potential of high-dose inhaled nitric oxide for antimicrobial effects: a narrative review and future directions,” was published in Intensive Care Medicine Experimental (ICMx), a journal of the European Society of Intensive Care Medicine. It presents evidence that high-dose iNO may serve as a broad-spectrum antimicrobial therapy for respiratory infections.
The article synthesizes clinical and mechanistic data from 27 studies conducted in both in-hospital and at-home settings. These studies include early-phase clinical trials in pneumonia, COVID-19, bronchiolitis, and nontuberculous mycobacteria (NTM) to illustrate the scope of ongoing research.
The paper highlights the multimodal activity of high-dose iNO, including direct microbial killing, biofilm disruption, antiviral effects, inflammation reduction, and enhanced mucociliary clearance. It also outlines a potential roadmap for future research, emphasizing opportunities in hospital-acquired pneumonia, ventilator-associated pneumonia, tuberculosis, post-viral fibrosis, and in immunocompromised patients.
Steve Lisi, Chief Executive Officer of Beyond Air, stated that the company is excited to see the scientific community increasingly recognize high-dose iNO as a potential antimicrobial platform for respiratory infections. Lisi added that a growing collection of studies shows that high-dose iNO can address pathogens and clinical challenges that current therapies are unable to treat and that this most recent article builds on the momentum of Beyond Air’s own clinical programs that have demonstrated promising signals in NTM, bronchiolitis, community-acquired pneumonia (VCAP), and COVID-19.
Beyond Air has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure and is currently advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).
Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting.
Beyond Air’s LungFit is a cylinder-free, phasic flow generator and delivery system designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator-compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm.
The LungFit system could potentially replace large, high-pressure NO cylinders, providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety by eliminating NO2 purging steps, and offering other operational benefits.
LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g., NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.
*Beyond Air’s LungFit PH is approved for commercial use in the United States, European Union, and many other countries around the world. Beyond Air’s other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.
Source: Beyond Air
